CG Oncology reports FY2024 net loss $88.0M; cash $742M; cretostimogene CR rate 75.5%

CG Oncology, Inc.

Net loss attributable to common stockholders $88.0M ($1.41/share) vs $67.8M ($15.65/share) in FY2023.
Cash and marketable securities $742.0M as of Dec 31, 2024; $238M oversubscribed equity offering extends runway to H1 2028.
Cretostimogene monotherapy achieved 75.5% complete response rate in BOND-003; median DoR exceeds 28 months.
R&D expenses $82.1M in FY2024 (up from $45.8M); G&A expenses $33.7M (up from $9.9M).
BLA submission for cretostimogene in HR BCG-unresponsive NMIBC anticipated H2 2025; CORE-008 topline data expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.